Your browser doesn't support javascript.
loading
Design and synthesis of a new series of 3,5-disubstituted isoxazoles active against Trypanosoma cruzi and Leishmania amazonensis.
da Rosa, Rafael; de Moraes, Milene Höehr; Zimmermann, Lara Almida; Schenkel, Eloir Paulo; Steindel, Mario; Bernardes, Lílian Sibelle Campos.
Afiliação
  • da Rosa R; Pharmaceutical and Medicinal Chemistry Laboratory, Department of Pharmaceutical Sciences, Federal University of Santa Catarina, Florianópolis, 88040-900 SC, Brazil.
  • de Moraes MH; Protozoology Laboratory, Department of Microbiology, Immunology and Parasitology, Federal University of Santa Catarina, Florianópolis, 88040-900 SC, Brazil.
  • Zimmermann LA; Pharmaceutical and Medicinal Chemistry Laboratory, Department of Pharmaceutical Sciences, Federal University of Santa Catarina, Florianópolis, 88040-900 SC, Brazil.
  • Schenkel EP; Pharmaceutical and Medicinal Chemistry Laboratory, Department of Pharmaceutical Sciences, Federal University of Santa Catarina, Florianópolis, 88040-900 SC, Brazil.
  • Steindel M; Protozoology Laboratory, Department of Microbiology, Immunology and Parasitology, Federal University of Santa Catarina, Florianópolis, 88040-900 SC, Brazil.
  • Bernardes LSC; Pharmaceutical and Medicinal Chemistry Laboratory, Department of Pharmaceutical Sciences, Federal University of Santa Catarina, Florianópolis, 88040-900 SC, Brazil. Electronic address: l.bernardes@ufsc.br.
Eur J Med Chem ; 128: 25-35, 2017 Mar 10.
Article em En | MEDLINE | ID: mdl-28152426
ABSTRACT
Chagas disease and leishmaniasis are neglected tropical diseases (NTDs) endemic in developing countries. Although there are drugs available for their treatment, efforts on finding new efficacious therapies are continuous. The natural lignans grandisin (1) and veraguensin (2) show activity against trypomastigote T. cruzi and their scaffold has been used as inspiration to design new derivatives with improved potency and chemical properties. We describe here the planning and microwave-irradiated synthesis of 26 isoxazole derivatives based on the structure of the lignans 1 and 2. In addition, the in vitro evaluation against culture trypomastigotes and intracellular amastigotes of T. cruzi and intracellular amastigotes of L. amazonensis and L. infantum is reported. Among the synthesized derivatives, compounds 17 (IC50 = 5.26 µM for T. cruzi), 29 (IC50 = 1.74 µM for T. cruzi) and 31 (IC50 = 1.13 µM for T. cruzi and IC50 = 5.08 µM for L. amazonensis) were the most active and were also evaluated against recombinant trypanothione reductase of T. cruzi in a preliminary study of their mechanism of action.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 2_ODS3 / 3_ND Base de dados: MEDLINE Assunto principal: Trypanosoma cruzi / Leishmania mexicana / Desenho de Fármacos / Leishmaniose / Leishmania infantum / Isoxazóis / Antiprotozoários Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Eur J Med Chem Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 2_ODS3 / 3_ND Base de dados: MEDLINE Assunto principal: Trypanosoma cruzi / Leishmania mexicana / Desenho de Fármacos / Leishmaniose / Leishmania infantum / Isoxazóis / Antiprotozoários Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Eur J Med Chem Ano de publicação: 2017 Tipo de documento: Article